NASDAQ: AGENAgenus Inc Stock
$7.85+0.63 (+8.73%)
Updated Sep 18, 2026
AGEN Price
$7.85
Fair Value Price
N/A
Market Cap
$353.41M
52 Week Low
$2.71
52 Week High
$8.84
P/E
2.96x
P/B
-1.78x
P/S
0.95x
PEG
0.56x
Dividend Yield
N/A
Revenue
$132.69M
Earnings
$92.01M
Gross Margin
99.5%
Operating Margin
113.88%
Profit Margin
69.2%
Debt to Equity
-1.9
Operating Cash Flow
-$99M
Beta
1.77
Next Earnings
Nov 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AGEN Overview
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AGEN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AGEN
Ranked#153 of 461
Ranked#153 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.60 | A | |
| $350.84 | A | |
| $42.02 | A |
Be the first to know about important AGEN news, forecast changes, insider trades & much more!
AGEN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGEN ($7.85) is trading below its intrinsic value of $17.00, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGEN is good value based on its earnings relative to its share price (2.96x), compared to the US market average (44.48x)
P/E vs Market Valuation
AGEN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AGEN due diligence checks available for Premium users.
Valuation
AGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.96x
Industry
9.29x
Market
44.48x
AGEN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AGEN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.78x
Industry
5.28x
AGEN price to earnings growth (PEG)
For valuing profitable companies with growth potential
AGEN is good value based... subscribe to Premium to read more.
PEG Value Valuation
AGEN's financial health
Profit margin
Revenue
$34.5M
Net Income
-$550.0k
Profit Margin
-1.7%
AGEN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AGEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$172.7M
Liabilities
$378.5M
Debt to equity
-1.9
AGEN's short-term liabilities ($231.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGEN's long-term liabilities ($146.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.2M
Investing
$267.0k
Financing
$14.7M
AGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGEN vs Biotech Stocks
Agenus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.